Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas.

Clinically relevant animal models of mammary carcinogenesis are crucial for the development and evaluation of new breast cancer chemopreventive agents. The neu-induced retroviral rat mammary carcinogenesis model is based on the direct in situ transfer of the activated neu oncogene into the mammary epithelium using a replication-defective retroviral vector. The resulting mammary carcinomas in intact Wistar-Furth rats exhibit a mixed hormonal response in the same proportion as has been observed in women. In intact rats, approximately 50% of mammary carcinomas can be prevented by tamoxifen treatment. In ovariectomized animals, the mammary carcinomas are hormonally nonresponsive and cannot be prevented by tamoxifen. We evaluated the efficacy of retinoic X receptor-selective retinoids (rexinoids) in this novel model of mammary carcinogenesis. The rexinoids LG100268 and bexarotene (LG1069, Targretin) were highly efficacious in the prevention of neu-induced mammary carcinomas. Dietary LG100268 at 100 mg/kg diet decreased tumor multiplicity by 32% (P = 0.0114) in intact rats and 50% (P < 0.0001) in ovariectomized rats. Bexarotene treatment at a dose of 250 mg/kg diet was associated with reductions in tumor multiplicity of 84% (P < 0.0001) and 86% (P < 0.0001) in intact and ovariectomized animals, respectively. In addition to tumor multiplicity, proliferation and apoptosis were modulated by bexarotene treatment independently of estrogen signaling. The neu-induced retroviral rat mammary carcinogenesis model represents a valuable addition to existing rodent chemoprevention models. The model is useful for assessing the efficacy of chemopreventive agents, specifically those compounds that target hormonally nonresponsive tumors.

[1]  K. Bland,et al.  Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers. , 2006, Carcinogenesis.

[2]  V. Steele,et al.  Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis. , 2004, Carcinogenesis.

[3]  A. Tari,et al.  How retinoids regulate breast cancer cell proliferation and apoptosis , 2004, Cellular and Molecular Life Sciences CMLS.

[4]  V. Steele,et al.  Cell Proliferation, Apoptosis, and Expression of Cyclin D1 and Cyclin E as Potential Biomarkers in Tamoxifen-Treated Mammary Tumors , 2003, Breast Cancer Research and Treatment.

[5]  S. Hilsenbeck,et al.  The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. , 2002, Cancer research.

[6]  M. Sporn,et al.  Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  M Baum,et al.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.

[8]  S. Hilsenbeck,et al.  Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  L. Norton,et al.  The MORE Trial: Multiple Outcomes for Raloxifene Evaluation , 2001, Annals of the New York Academy of Sciences.

[10]  K. Korach,et al.  Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression. , 2000, Cancer research.

[11]  Cheryl Jorcyk,et al.  The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma , 2000, Oncogene.

[12]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[13]  V. Steele,et al.  Progress in Cancer Chemoprevention , 1999, Annals of the New York Academy of Sciences.

[14]  A. Mondzac.  Tamoxifen: a Guide for Clinicians and Patients Craig Jordan, ed. Huntington (NY): PRR, Inc., 1996. 216 pp., illus. $39.95. ISBN 9641823-4-3 , 1998 .

[15]  M. Gottardis,et al.  Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. , 1996, Cancer research.

[16]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[17]  J. Green,et al.  Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[20]  M. Lindstrom,et al.  Difference in the response of neu and ras oncogene-induced rat mammary carcinomas to early and late ovariectomy. , 1992, Cancer research.

[21]  M. Lindstrom,et al.  Frequent induction of mammary carcinomas following neu oncogene transfer into in situ mammary epithelial cells of susceptible and resistant rat strains. , 1991, Cancer research.

[22]  M. Lindstrom,et al.  Carcinoma induction following direct in situ transfer of v-Ha-ras into rat mammary epithelial cells using replication-defective retrovirus vectors. , 1991, Cancer research.

[23]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[24]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[25]  R. Tallarida,et al.  An evaluation of tamoxifen as a partial agonist by classical receptor theory--an explanation of the dual action of tamoxifen. , 1984, European journal of pharmacology.

[26]  H. Gratzner,et al.  Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication. , 1982, Science.

[27]  G. Bots,et al.  Tumours in the mammary gland induced in Lewis rats by intravenous methylnitrosurea. , 1975, British Journal of Cancer.

[28]  P. Gullino,et al.  N-nitrosomethylurea as mammary gland carcinogen in rats. , 1975, Journal of the National Cancer Institute.

[29]  R. Geyer,et al.  Effect of dose and hormones on tumor production in rats given emulsified 9, 10-dimethyl-1,2-benzanthracene intravenously. , 1953, Cancer research.

[30]  R. Geyer,et al.  Tumor production in rats injected intravenously with oil emulsions containing 9,10-dimethyl-1,2-benzanthracene. , 1951, Cancer research.

[31]  M. Lerner,et al.  Prevention of DMBA-induced rat mammary carcinomas comparing leuprolide, oophorectomy, and tamoxifen , 2004, Breast Cancer Research and Treatment.

[32]  T. Thompson,et al.  Direct Gene Transfer into the Mammary Epithelium In Situ Using Retroviral Vectors , 2000 .

[33]  B. Asch,et al.  Methods in Mammary Gland Biology and Breast Cancer Research , 2000, Springer US.

[34]  M. Sporn,et al.  The Retinoids : biology, chemistry, and medicine , 1994 .

[35]  M. Gould.  The introduction of activated oncogenes to mammary cells in vivo using retroviral vectors: A new model for the chemoprevention of premalignant and malignant lesions of the breast , 1993, Journal of cellular biochemistry. Supplement.

[36]  M. Sporn,et al.  Cellular biology and biochem-istry of the retinoids , 1984 .